2 unknown, 1 not yet recruiting. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Unknown 2, Not yet recruiting 1 |
Follow Yang Jianjun, PhD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma Serplulimab Combined With Nab-paclitaxel and Cisplatin, nab-paclitaxel，Cisplatin - Esophageal Squamous Cell Carcinoma | Phase 4 | Not yet recruiting | Yang Jianjun, PhD | 80 | 2024-05-01 | 2024-04-29 |
| Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma Adebrelimab combined with SOX regimen, Placebo combined with SOX (S-1/oxaliplatin) regimen - Locally Advanced Gastric Adenocarcinoma | Phase 4 | Unknown | Yang Jianjun, PhD | 110 | 2023-12-30 | 2024-01-29 |
| Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab, nab-paclitaxel, lobaplatin, and S-1 - Advanced Gastric Cancer | Phase 4 | Unknown | Yang Jianjun, PhD | 140 | 2023-12-30 | 2024-01-23 |
Esophageal Squamous Cell Carcinoma (1)
130-nm albumin-bound paclitaxel (2) · Cisplatin (1) · Clinical Protocols (1) · Ramucirumab (1) · S 1 (combination) (1) · lobaplatin (1)
China (2)